CSF2 and melanoma: Indeed, vaccines using DC-specific immune adjuvant (particularly GM-CSF) can alter the number and activation status of DCs residing in melanoma SLN (Lana et al, 2001; Lee et al, 2005) and can induce the activation of peripheral blood lymphocytes resulting in some positive clinical responses (Vuylsteke et al, 2006).